BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 12782937)

  • 1. Thalidomide analogs as emerging anti-cancer drugs.
    Dredge K; Dalgleish AG; Marriott JB
    Anticancer Drugs; 2003 Jun; 14(5):331-5. PubMed ID: 12782937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Properties of thalidomide and its analogues: implications for anticancer therapy.
    Teo SK
    AAPS J; 2005 Mar; 7(1):E14-9. PubMed ID: 16146335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thalidomide derived immunomodulatory drugs (IMiDs) as potential therapeutic agents.
    Marriott JB; Dredge K; Dalgleish AG
    Curr Drug Targets Immune Endocr Metabol Disord; 2003 Sep; 3(3):181-6. PubMed ID: 12871024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunological effects of thalidomide and its chemical and functional analogs.
    Dredge K; Marriott JB; Dalgleish AG
    Crit Rev Immunol; 2002; 22(5-6):425-37. PubMed ID: 12803319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thalidomide: a novel template for anticancer drugs.
    Stirling D
    Semin Oncol; 2001 Dec; 28(6):602-6. PubMed ID: 11740817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunomodulatory properties of thalidomide analogs: pomalidomide and lenalidomide, experimental and therapeutic applications.
    Bodera P; Stankiewicz W
    Recent Pat Endocr Metab Immune Drug Discov; 2011 Sep; 5(3):192-6. PubMed ID: 21913886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells.
    Marriott JB; Clarke IA; Dredge K; Muller G; Stirling D; Dalgleish AG
    Clin Exp Immunol; 2002 Oct; 130(1):75-84. PubMed ID: 12296856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects.
    Dredge K; Marriott JB; Macdonald CD; Man HW; Chen R; Muller GW; Stirling D; Dalgleish AG
    Br J Cancer; 2002 Nov; 87(10):1166-72. PubMed ID: 12402158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IMiDs: a novel class of immunomodulators.
    Knight R
    Semin Oncol; 2005 Aug; 32(4 Suppl 5):S24-30. PubMed ID: 16085014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological properties of thalidomide and its analogues.
    De Sanctis JB; Mijares M; Suárez A; Compagnone R; Garmendia J; Moreno D; Salazar-Bookaman M
    Recent Pat Inflamm Allergy Drug Discov; 2010 Jun; 4(2):144-8. PubMed ID: 20307255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs.
    Schafer PH; Gandhi AK; Loveland MA; Chen RS; Man HW; Schnetkamp PP; Wolbring G; Govinda S; Corral LG; Payvandi F; Muller GW; Stirling DI
    J Pharmacol Exp Ther; 2003 Jun; 305(3):1222-32. PubMed ID: 12649301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The evolution of thalidomide and its IMiD derivatives as anticancer agents.
    Bartlett JB; Dredge K; Dalgleish AG
    Nat Rev Cancer; 2004 Apr; 4(4):314-22. PubMed ID: 15057291
    [No Abstract]   [Full Text] [Related]  

  • 13. Potential new therapeutics for Waldenstrom's macroglobulinemia.
    Zeldis JB; Schafer PH; Bennett BL; Mercurio F; Stirling DI
    Semin Oncol; 2003 Apr; 30(2):275-81. PubMed ID: 12720152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thalidomide and lenalidomide in the treatment of multiple myeloma.
    Kumar S; Rajkumar SV
    Eur J Cancer; 2006 Jul; 42(11):1612-22. PubMed ID: 16750621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma.
    Quach H; Ritchie D; Stewart AK; Neeson P; Harrison S; Smyth MJ; Prince HM
    Leukemia; 2010 Jan; 24(1):22-32. PubMed ID: 19907437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thalidomide-derived immunomodulatory drugs as therapeutic agents.
    Galustian C; Labarthe MC; Bartlett JB; Dalgleish AG
    Expert Opin Biol Ther; 2004 Dec; 4(12):1963-70. PubMed ID: 15571458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thalidomide analogues as anticancer drugs.
    Aragon-Ching JB; Li H; Gardner ER; Figg WD
    Recent Pat Anticancer Drug Discov; 2007 Jun; 2(2):167-74. PubMed ID: 17975653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Thalidomide: mechanisms of action and new insights in hematology].
    Leleu X; Micol JB; Guieze R; Berthon C; Kuhnovsky F; Terriou L; Moreau AS; Yakoub-Agha I; Bauters F; Facon T
    Rev Med Interne; 2005 Feb; 26(2):119-27. PubMed ID: 15710258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thalidomide and immunomodulatory drugs as cancer therapy.
    Raje N; Anderson KC
    Curr Opin Oncol; 2002 Nov; 14(6):635-40. PubMed ID: 12409654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The thalidomide saga.
    Melchert M; List A
    Int J Biochem Cell Biol; 2007; 39(7-8):1489-99. PubMed ID: 17369076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.